BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Given Consensus Rating of “Moderate Buy” by Analysts

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) has received a consensus rating of “Moderate Buy” from the six brokerages that are currently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, three have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $42.60.

Several brokerages have recently commented on BTAI. HC Wainwright cut their price objective on BioXcel Therapeutics from $80.00 to $48.00 and set a “buy” rating for the company in a report on Thursday, January 30th. RODMAN&RENSHAW raised shares of BioXcel Therapeutics to a “strong-buy” rating in a report on Wednesday, March 19th. Finally, Rodman & Renshaw initiated coverage on shares of BioXcel Therapeutics in a report on Wednesday, March 19th. They set a “buy” rating and a $65.00 price objective for the company.

Institutional Investors Weigh In On BioXcel Therapeutics

Institutional investors have recently made changes to their positions in the business. Squarepoint Ops LLC lifted its stake in BioXcel Therapeutics by 203.9% in the fourth quarter. Squarepoint Ops LLC now owns 72,046 shares of the company’s stock worth $27,000 after purchasing an additional 48,336 shares during the last quarter. Northern Trust Corp boosted its holdings in BioXcel Therapeutics by 81.4% during the 4th quarter. Northern Trust Corp now owns 73,910 shares of the company’s stock valued at $28,000 after acquiring an additional 33,161 shares during the period. Wells Fargo & Company MN grew its position in BioXcel Therapeutics by 7.5% during the 4th quarter. Wells Fargo & Company MN now owns 199,010 shares of the company’s stock worth $74,000 after acquiring an additional 13,952 shares during the last quarter. Finally, Geode Capital Management LLC increased its stake in BioXcel Therapeutics by 4.7% in the 4th quarter. Geode Capital Management LLC now owns 311,965 shares of the company’s stock worth $117,000 after purchasing an additional 13,922 shares during the period. Hedge funds and other institutional investors own 30.68% of the company’s stock.

BioXcel Therapeutics Trading Down 3.2 %

BioXcel Therapeutics stock opened at $1.53 on Friday. BioXcel Therapeutics has a 1-year low of $1.29 and a 1-year high of $37.28. The firm has a market capitalization of $8.39 million, a PE ratio of -0.04 and a beta of 0.08. The firm’s 50 day simple moving average is $2.00 and its 200 day simple moving average is $4.85.

BioXcel Therapeutics (NASDAQ:BTAI) last issued its quarterly earnings data on Thursday, March 27th. The company reported ($3.57) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($4.36) by $0.79. The business had revenue of $0.30 million during the quarter, compared to analysts’ expectations of $0.72 million. Research analysts forecast that BioXcel Therapeutics will post -24.39 earnings per share for the current year.

About BioXcel Therapeutics

BioXcel Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices.